Next Article in Journal
Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses
Previous Article in Journal
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex
Article Menu

Export Article

Open AccessArticle
Vaccines 2016, 4(2), 17; doi:10.3390/vaccines4020017

Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions

1
GSK Vaccines, 7030 Kit Creek Road, Morrisville, NC 27560, USA
2
GSK Vaccines, 1330 Rixensart, Belgium
3
GSK Vaccines, Cambridge, MA 02139, USA
*
Author to whom correspondence should be addressed.
Academic Editor: XiaoJian Yao
Received: 14 March 2016 / Revised: 12 April 2016 / Accepted: 25 April 2016 / Published: 13 May 2016
View Full-Text   |   Download PDF [3694 KB, uploaded 13 May 2016]   |  

Abstract

Two HIV-1 subtype C gp120 protein candidates were the selected antigens for several experimental vaccine regimens now under evaluation in HVTN 100 Phase I/II clinical trial aiming to support the start of the HVTN 702 Phase IIb/III trial in southern Africa, which is designed to confirm and extend the partial protection seen against HIV-1 infection in the RV144 Thai trial. Here, we report the comprehensive physicochemical characterization of the gp120 reference materials that are representative of the clinical trial materials. Gp120 proteins were stably expressed in Chinese Hamster Ovary (CHO) cells and subsequently purified and formulated. A panel of analytical techniques was used to characterize the physicochemical properties of the two protein molecules. When formulated in the AS01 Adjuvant System, the bivalent subtype C gp120 antigens elicited 1086.C- and TV1.C-specific binding antibody and CD4+ T cell responses in mice. All the characteristics were highly representative of the Clinical Trial Materials (CTM). Data from this report demonstrate the immunogenicity of the gp120 antigens, provide comprehensive characterization of the molecules, set the benchmark for assessment of current and future CTM lots, and lay the physicochemical groundwork for interpretation of future clinical trial data. View Full-Text
Keywords: vaccine; antigens; gp120; HIV-1; clinical trial; characterization; immunogenicity vaccine; antigens; gp120; HIV-1; clinical trial; characterization; immunogenicity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Wang, Z.; Lorin, C.; Koutsoukos, M.; Franco, D.; Bayat, B.; Zhang, Y.; Carfi, A.; Barnett, S.W.; Porter, F. Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions. Vaccines 2016, 4, 17.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top